UK markets closed

Compass Therapeutics, Inc. (CMPX)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
4.3700-0.0800 (-1.80%)
At close: 01:00PM EST
Currency in USD

Valuation measures4

Market cap (intra-day) 551.46M
Enterprise value 434.07M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)4.75
Enterprise value/revenue N/A
Enterprise value/EBITDA -11.20

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 343.28%
S&P500 52-week change 3-13.51%
52-week high 34.8500
52-week low 31.2500
50-day moving average 33.3112
200-day moving average 32.5585

Share statistics

Avg vol (3-month) 3189.81k
Avg vol (10-day) 3121.59k
Shares outstanding 5126.19M
Implied shares outstanding 6N/A
Float 899.24M
% held by insiders 114.96%
% held by institutions 148.12%
Shares short (30 Oct 2022) 4131.04k
Short ratio (30 Oct 2022) 41.56
Short % of float (30 Oct 2022) 40.18%
Short % of shares outstanding (30 Oct 2022) 40.13%
Shares short (prior month 29 Sept 2022) 4193.36k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)29 Sept 2022

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-32.08%
Return on equity (ttm)-58.02%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -41.06M
Net income avi to common (ttm)-40.61M
Diluted EPS (ttm)-1.0890
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)120.6M
Total cash per share (mrq)0.96
Total debt (mrq)3.22M
Total debt/equity (mrq)2.77
Current ratio (mrq)12.80
Book value per share (mrq)1.15

Cash flow statement

Operating cash flow (ttm)-28.15M
Levered free cash flow (ttm)-13.01M